药物信息为ZIRGAN (ganciclovir ophthalmic gel) 0.15%Initial U.S. Approval: 1989 (Sirion Therapeutics, Inc.): 1 INDICATIONS AND USAGE
- 1 INDICATIONS AND USAGE
- 2 DOSAGE AND ADMINISTRATION
- 3 DOSAGE FORMS AND STRENGTHS
- 4 CONTRAINDICATIONS
- 5 WARNINGS AND PRECAUTIONS
- 6 ADVERSE REACTIONS
- 8 USE IN SPECIFIC POPULATIONS
- 11 DESCRIPTION
- 12 CLINICAL PHARMACOLOGY
- 13 NONCLINICAL TOXICOLOGY
- 14 CLINICAL STUDIES
- 16 HOW SUPPLIED/STORAGE AND HANDLING
- 17 PATIENT COUNSELING INFORMATION
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 5 gm TUBE
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 5 gm CARTON
- 外部链接相关的ZIRGAN (ganciclovir ophthalmic gel) 0.15%Initial U.S. Approval: 1989 (Sirion Therapeutics, Inc.)
ZIRGAN (ganciclovir ophthalmic gel) 0.15% is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
- Drug Information Provided by National Library of Medicine (NLM).
这个站点被设计主要作为提示系统供合格的医师和其他医疗专家使用。 通过使用这个站点您了解并且接受DiagnosisPro.com不会使用作为一个诊断决策系统，并且不能使用做一个临床诊断或替换或者否决一位被准许的医疗保健专家的评断或临床诊断 (充分的使用条款). 我们遵循健康网络基金会的 医学和健康网站的行为准则. 点击这里核实
© 2012 MedTech USA, Inc. (最后更新在05/25/12)
